Navigation Links
NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
Date:4/22/2009

DENVER and SAN CARLOS, Calif., April 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented data today at the American Association for Cancer Research (AACR) 100th Annual Meeting demonstrating that NKTR-105, a novel PEGylated form of docetaxel, has superior antitumor activity, as well as greater and sustained exposure in plasma and tumor tissue, over docetaxel in preclinical models.

In a comparative study of NKTR-105 and docetaxel, NKTR-105 treatment significantly delayed tumor growth as compared to docetaxel (122% v. 48%), which was associated with greater and sustained tumor exposure to docetaxel after NKTR-105 administration. Treatment with NKTR-105 increased docetaxel concentrations in tumors (0.4 to 4-fold higher) and resulted in an improved time-concentration profile (2-fold greater) as compared to docetaxel in a non-small cell lung (H460) mouse xenograft model.

"The encouraging antitumor activity and unique pharmacokinetic profile of NKTR-105 in these data support our ongoing Phase 1 study in patients with refractory solid cancers," said Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer. "We believe NKTR-105 has the potential to offer improved efficacy as well as improved safety and tolerability due to its prolonged half-life and increased uptake by tumor tissue relative to docetaxel. We are excited about the drug's potential to significantly expand therapeutic options for oncologists and patients."

In previous preclinical studies, NKTR-105 demonstrated superior antitumor activity with no neutropenia in multiple tumor models, indicating that NKTR-105 may enable sustained therapeutic levels of docetaxel without the myelosuppression that is a dose-limiting toxicity for this widely-used cancer therapy.

NKTR-105 is currently being evaluated in a Phase 1 clinical trial in cancer patients. The Phase 1 study will assess the safety, pharmacokinetics and antitumor activity of NKTR-105 in approximately 30 patients with refractory solid tumors who have failed all prior available therapies. In the current trial of NKTR-105, the compound has required no pre-treatment with corticosteroids and shown no evidence of neutropenia in patients to date.

About NKTR-105

NKTR-105 is a novel form of docetaxel that was developed using Nektar's advanced polymer technology platform. The compound belongs to the taxoid family and acts by disrupting the microtubular network in cells. It is being developed as an anti-neoplastic agent, and is the company's second oncology program in clinical development.

Docetaxel is a versatile chemotherapy agent currently approved by the FDA for use in breast, non-small cell lung, prostate, gastric, and head and neck cancers. Oncolytics such as docetaxel typically have sub-optimal half-lives which can limit their therapeutic efficacy, or have a safety and tolerability profile that limits their use. Nektar's advanced polymer conjugate technology platform has the potential to be used to optimize the bioactivity of these small molecule compounds and increase the sustained exposure of active drug to tumor cells in the body. Annual sales of docetaxel are in excess of $2 billion worldwide.

Data Presentation for NKTR-105

The poster presentation from today's session entitled "Novel Agents 4" can be found on Nektar's website at www.nektar.com/product_pipeline/oncology_nktr-105.html.

AACR 2009: Abstract #5566: "NKTR-105 demonstrates superior antitumor activity over docetaxel in a NSCLC mouse xenograft model and increases tumor docetaxel exposure."

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.

This press release contains forward-looking statements that reflect the company's current views regarding the potential of the Company's technology platforms and the potential of NKTR-105. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) NKTR-105 is in the early stages of clinical development and the risk of failure is high and can unexpectedly occur at any time; (ii) the timing or success of the commencement or end of clinical trials may be delayed or unsuccessful due to slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical trial design, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (iii) clinical trials are long, expensive and uncertain processes and the risk of failure of any product that is in clinical development and prior to regulatory approval remains high and can occur at any stage due to efficacy, safety or other factors; (iv) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future; and (v) the outcome of any existing or future intellectual property or other litigation related to Nektar's proprietary product candidates. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. For more information on Nektar Therapeutics, please visit www.nektar.com.

    Contact:
    Jennifer Ruddock, 650-631-4954
    Nektar Therapeutics


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors
2. Fish researcher demonstrates first non-visual feeding by African cichlids
3. Harris Corporation Demonstrates Global Medical Imagery Access, Sharing and Collaboration Capabilities
4. Edmond Scientific Company Demonstrates RHIO/HIE Data Security and Privacy Solution for the NHIN at Annual HIMSS Conference, Chicago 09
5. Stanford Study on CyberKnife Radiosurgery for Prostate Cancer Demonstrates 100 Percent PSA Response at 33 months
6. Siemens Demonstrates Workflow Efficiency in Echocardiography at ACC 2009
7. Siemens Demonstrates Flash Speed, Lowest Dose at ACC 2009
8. New published study demonstrates over-the-counter device lowers blood pressure in diabetic patients
9. MU researcher demonstrates non-traditional therapy is effective as pain management
10. IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte(R) (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients
11. Bay Valleys French Style Dressing Demonstrates Z Trims Value to Private Label and Store Brands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology: